GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Vaccine Biologics Corp (ROCO:6547) » Definitions » EV-to-EBITDA

Medigen Vaccine Biologics (ROCO:6547) EV-to-EBITDA : 127.14 (As of May. 22, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Medigen Vaccine Biologics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medigen Vaccine Biologics's enterprise value is NT$15,467.6 Mil. Medigen Vaccine Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was NT$121.7 Mil. Therefore, Medigen Vaccine Biologics's EV-to-EBITDA for today is 127.14.

The historical rank and industry rank for Medigen Vaccine Biologics's EV-to-EBITDA or its related term are showing as below:

ROCO:6547' s EV-to-EBITDA Range Over the Past 10 Years
Min: -142.56   Med: -15.78   Max: 225.15
Current: 127.15

During the past 13 years, the highest EV-to-EBITDA of Medigen Vaccine Biologics was 225.15. The lowest was -142.56. And the median was -15.78.

ROCO:6547's EV-to-EBITDA is ranked worse than
94.95% of 495 companies
in the Biotechnology industry
Industry Median: 8.09 vs ROCO:6547: 127.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-22), Medigen Vaccine Biologics's stock price is NT$51.70. Medigen Vaccine Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-0.082. Therefore, Medigen Vaccine Biologics's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Medigen Vaccine Biologics EV-to-EBITDA Historical Data

The historical data trend for Medigen Vaccine Biologics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Vaccine Biologics EV-to-EBITDA Chart

Medigen Vaccine Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.71 40.30 -15.48 -21.44 137.24

Medigen Vaccine Biologics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.12 -31.46 -27.93 137.24 117.82

Competitive Comparison of Medigen Vaccine Biologics's EV-to-EBITDA

For the Biotechnology subindustry, Medigen Vaccine Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's EV-to-EBITDA falls into.


;
;

Medigen Vaccine Biologics EV-to-EBITDA Calculation

Medigen Vaccine Biologics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=15467.619/121.654
=127.14

Medigen Vaccine Biologics's current Enterprise Value is NT$15,467.6 Mil.
Medigen Vaccine Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$121.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Vaccine Biologics  (ROCO:6547) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Medigen Vaccine Biologics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=51.70/-0.082
=At Loss

Medigen Vaccine Biologics's share price for today is NT$51.70.
Medigen Vaccine Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.082.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Medigen Vaccine Biologics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medigen Vaccine Biologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Vaccine Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 16, Neihu Road, Lane 120, Floor 7, Section 1, Neihu District, Taipei, TWN, 11493
Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of Covid-19 vaccines and Covid-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.

Medigen Vaccine Biologics Headlines

No Headlines